))
James Gilligan is Leading the Next Wave of Psilocybin
Manage episode 379513587 series 3342868
Sisällön tarjoaa PsychedelicInvest.com. PsychedelicInvest.com tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Welcome to the fourth season of the Psychedelic Invest Podcast! It's great to be back!
On the season premiere episode, host Bruce Eckfeldt is joined by James Gilligan, the CEO of Tryp Therapeutics.
Jim received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut; he continued his post graduate education at the Roche Institute of Molecular Biology
Following his postdoc, Jim was a co-founder of Unigene Labs, which became experts in the development of peptide based therapeutics. During his tenure at Unigene he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies.
Jim transitioned from R&D to business development (BD) and during this time obtained a Masters in International Business from Seton Hall University (South Orange, NJ). As VP for product and business development he established a biotech joint venture in China. He was responsible for executing numerous feasibility and licensing deals with the Pharma Industry. As part of his BD responsibilities he worked frequently with investment bankers, venture capitalists, and brokers.
Following his time at Unigene Jim was a co-founder and CSO of Tarsa Therapeutics.
50 jaksoa
Jaa
